Results 41 to 50 of about 9,275 (242)

Nav1.7-P610T mutation in 2 siblings with persistent ocular pain after corneal axon transection: impaired slow-inactivation and hyperexcitable trigeminal neurons.

open access: yesJournal of Neurophysiology, 2023
Despite extensive study, the mechanisms underlying pain after axonal injury remain incompletely understood. Pain after corneal refractive surgery provides a model, in humans, of the effect of injury to trigeminal afferent nerves.
Mohammad-Reza Ghovanloo   +6 more
semanticscholar   +1 more source

Intranasal CRMP2-Ubc9 Inhibitor Regulates NaV1.7 to Alleviate Trigeminal Neuropathic Pain

open access: yesbioRxiv, 2023
Dysregulation of voltage-gated sodium NaV1.7 channels in sensory neurons contributes to chronic pain conditions, including trigeminal neuropathic pain.
Santiago Loya-López   +11 more
semanticscholar   +2 more sources

Progesterone Attenuates Allodynia of Inflamed Temporomandibular Joint through Modulating Voltage-Gated Sodium Channel 1.7 in Trigeminal Ganglion

open access: yesPain Research and Management, 2020
Background. Women with temporomandibular disorders (TMDs) experience some amelioration of pain during pregnancy. Progesterone increases dramatically and steadily during pregnancy. Sodium channel 1.7 (Nav1.7) plays a prominent role in pain perceptions, as
Rui-Yun Bi   +4 more
doaj   +1 more source

An update on transcriptional and post-translational regulation of brain voltage-gated sodium channels [PDF]

open access: yes, 2015
Voltage-gated sodium channels are essential proteins in brain physiology, as they generate the sodium currents that initiate neuronal action potentials.
Beltran-Alvarez, Pedro   +1 more
core   +1 more source

Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine. [PDF]

open access: yesPLoS ONE, 2015
Mexiletine and lidocaine are widely used class IB anti-arrhythmic drugs that are considered to act by blocking voltage-gated open sodium currents for treatment of ventricular arrhythmias and relief of pain.
Ying Wang   +4 more
doaj   +1 more source

Nav1.7 withholds its pain potential [PDF]

open access: yesNature Reviews Drug Discovery, 2019
Despite compelling genetic validation, drug developers are struggling to unlock the therapeutic promise of the Nav1.7 sodium channel as a pain target. Despite compelling genetic validation, drug developers are struggling to unlock the therapeutic promise of the Nav1.7 sodium channel as a pain target.
openaire   +1 more source

Glial interleukin-1β upregulates neuronal sodium channel 1.7 in trigeminal ganglion contributing to temporomandibular joint inflammatory hypernociception in rats

open access: yesJournal of Neuroinflammation, 2018
Background The proinflammatory cytokine interleukin-1β (IL-1β) drives pain by inducing the expression of inflammatory mediators; however, its ability to regulate sodium channel 1.7 (Nav1.7), a key driver of temporomandibular joint (TMJ) hypernociception,
Peng Zhang, Rui-Yun Bi, Ye-Hua Gan
doaj   +1 more source

Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: The trigeminal neuralgia experience [PDF]

open access: yes, 2018
Background: This study aimed to describe recruitment challenges encountered during a phase IIa study of vixotrigine, a state and use-dependent Nav1.7 channel blocker, in individuals with trigeminal neuralgia.
Bendtsen, Lars   +10 more
core   +4 more sources

Membrane protein Nav1.7 contributes to the persistent post-surgical pain regulated by p-p65 in dorsal root ganglion (DRG) of SMIR rats model

open access: yesBMC Anesthesiology, 2017
Background Persistent post-surgical pain is a difficult clinical problem. In this study, we intend to explore the mechanism underlying the persistent post-surgical pain in SMIR (skin/muscle incision and retraction) rats.
Zhisong Li   +7 more
doaj   +1 more source

Lacosamide Inhibition of NaV1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore

open access: yesFrontiers in Pharmacology, 2021
Lacosamide, developed as an anti-epileptic drug, has been used for the treatment of pain. Unlike typical anticonvulsants and local anesthetics which enhance fast-inactivation and bind within the pore of sodium channels, lacosamide enhances slow ...
Julie I. R. Labau   +29 more
doaj   +1 more source

Home - About - Disclaimer - Privacy